Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 159.04 Thousand AUD | -24.4% |
| 2023 | 210.38 Thousand AUD | 79.07% |
| 2022 | 117.48 Thousand AUD | 78.97% |
| 2021 | 65.64 Thousand AUD | 94.53% |
| 2020 | 33.74 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| 2018 | - AUD | 0.0% |
| 2017 | - AUD | 0.0% |
| 2016 | - AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | -100.0% |
| 2013 | 802.64 Thousand AUD | 168.43% |
| 2012 | 299.01 Thousand AUD | 4.63% |
| 2011 | 285.78 Thousand AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 76.5 Thousand AUD | -63.64% |
| 2024 Q4 | 159.04 Thousand AUD | 0.0% |
| 2024 Q3 | - AUD | -100.0% |
| 2024 FY | 159.04 Thousand AUD | -24.4% |
| 2024 Q2 | 76.5 Thousand AUD | 0.0% |
| 2023 Q3 | 103.2 Thousand AUD | 251.85% |
| 2023 Q4 | 210.38 Thousand AUD | 103.85% |
| 2023 FY | 210.38 Thousand AUD | 79.07% |
| 2023 Q2 | 29.33 Thousand AUD | 0.0% |
| 2023 Q1 | 29.33 Thousand AUD | -75.03% |
| 2022 Q1 | 26.72 Thousand AUD | -59.29% |
| 2022 Q4 | 117.48 Thousand AUD | 96.28% |
| 2022 FY | 117.48 Thousand AUD | 78.97% |
| 2022 Q2 | 41.89 Thousand AUD | 56.75% |
| 2022 Q3 | 59.85 Thousand AUD | 42.88% |
| 2021 Q1 | - AUD | -100.0% |
| 2021 Q3 | 37.9 Thousand AUD | 0.0% |
| 2021 FY | 65.64 Thousand AUD | 94.53% |
| 2021 Q2 | - AUD | 0.0% |
| 2021 Q4 | 65.64 Thousand AUD | 73.2% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2020 Q3 | 868.00 AUD | 0.0% |
| 2020 Q4 | 33.74 Thousand AUD | 3787.9% |
| 2020 FY | 33.74 Thousand AUD | 0.0% |
| 2019 Q3 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| 2019 Q4 | - AUD | 0.0% |
| 2019 Q1 | - AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q3 | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2018 Q1 | - AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2017 FY | - AUD | 0.0% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 Q3 | - AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2016 FY | - AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 Q1 | - AUD | 0.0% |
| 2016 Q3 | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2014 Q1 | 839.66 Thousand AUD | 4.61% |
| 2014 FY | - AUD | -100.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 Q3 | - AUD | -100.0% |
| 2014 Q2 | 839.66 Thousand AUD | 0.0% |
| 2013 Q4 | 802.64 Thousand AUD | 0.0% |
| 2013 FY | 802.64 Thousand AUD | 168.43% |
| 2013 Q3 | 802.64 Thousand AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q4 | 299.01 Thousand AUD | 0.0% |
| 2012 FY | 299.01 Thousand AUD | 4.63% |
| 2011 FY | 285.78 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 Q2 | - AUD | 0.0% |
| 2009 Q2 | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 Q2 | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2006 Q2 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | - AUD | 0.0% |
| 2005 Q4 | - AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2005 Q2 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 Q2 | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 Q2 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 37.774% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 88.163% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 87.052% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.633% |
| GB Sciences, Inc. | 1.75 Million USD | 90.96% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | 96.554% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1455.452% |
| Agentix Corp. | 50 Thousand USD | -218.09% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 97.291% |
| Biomind Labs Inc. | 735.54 Thousand USD | 78.377% |
| ContraFect Corporation | 2.88 Million USD | 94.48% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| CytoDyn Inc. | 30.07 Million USD | 99.471% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 55.785% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 74.758% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.651% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 83.228% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 78.968% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.466% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.421% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 82.091% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.614% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 93.162% |
| Mesoblast Limited | 118.7 Million USD | 99.866% |
| Marizyme, Inc. | 18.71 Million USD | 99.15% |
| Genus plc | 233.1 Million USD | 99.932% |
| Pharming Group N.V. | 171.54 Million USD | 99.907% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 78.794% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 89.003% |
| IMV Inc. | 28.88 Million USD | 99.449% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 97.189% |
| MultiCell Technologies, Inc. | 202.58 USD | -78409.725% |
| ONE Bio Corp. | 19.71 Million USD | 99.193% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.723% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.52% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 94.744% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.776% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -12.385% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -518.395% |
| Alpha Cognition Inc. | 1.22 Million USD | 86.967% |
| Enzolytics Inc. | 996.33 Thousand USD | 84.037% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 99.205% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.751% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.962% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 96.142% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 60.422% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 93.367% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 30.636% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -6.99% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 94.573% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -17.388% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | 89.36% |
| Q BioMed Inc. | 4.1 Million USD | 96.13% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.218% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.765% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 96.624% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 92.958% |
| HST Global, Inc. | 98.31 Thousand USD | -61.764% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 36.055% |
| Halberd Corporation | 150 Thousand USD | -6.03% |
| Resverlogix Corp. | 6.49 Million USD | 97.55% |
| Cell Source, Inc. | 9.25 Million USD | 98.281% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.128% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 20.722% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | 92.77% |
| Kadimastem Ltd | 891.22 Thousand USD | 82.154% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 24.614% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 36.428% |
| LadRx Corporation | 33.6 Thousand USD | -373.264% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 78.968% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | 30.359% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 96.808% |
| Mobile Lads Corp. | 484.28 Thousand USD | 67.159% |
| International Stem Cell Corporation | 4.17 Million USD | 96.193% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | 91.738% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 54.797% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.966% |
| SYBLEU INC | 477.5 Thousand USD | 66.692% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -29.833% |
| Rebus Holdings, Inc. | 310 Thousand USD | 48.695% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 96.641% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -154.827% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 92.707% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 98.087% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 98.147% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 89.775% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 40.655% |
| Neutra Corp. | 54.15 Thousand USD | -193.679% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 91.309% |
| PureTech Health plc | 25.51 Million USD | 99.377% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 87.009% |
| IXICO plc | 472.02 Thousand USD | 66.306% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.974% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.745% |
| CSL Limited | 12.18 Billion USD | 99.999% |
| Cellectis S.A. | 92.77 Million USD | 99.829% |